TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8141572
Drug: Meropenem 1-g
Normalized name: meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 1-g intravenous intermittent infusions every 8 h
Study: 29782648
Drug: Topical treatments
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatments for AK
Study: 25315022
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with Unna's boot
Study: 21983154
Drug: Quadrivalent live
Normalized name: influenza vaccine quadrivalent live 2015-2016 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent live attenuated influenza vaccine (Q/LAIV), n=1200
Study: 21983154
Drug: Trivalent live
Normalized name: influenza vaccine trivalent live 2024-2025 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent live attenuated influenza vaccine (T/LAIV), n=600
Study: 17928802
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg iron daily for 8 weeks
Study: 17928802
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg iron daily for 8 weeks
Study: 17928802
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg iron daily for 8 weeks
Study: 17928802
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg iron group
Study: 17928802
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg iron group
Study: 15646910
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg of oral midazolam (MDZ) 20 minutes prior to treatment
Study: 15646910
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg oral midazolam (MDZ) with 3.7 mg/kg of hydroxyzine (MDZH) 30 minutes before treatment
Study: 15646910
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydroxyzine (3.7 mg/kg) with MDZ (0.3 mg/kg)
Study: 28796278
Drug: PNF stretching
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNF stretching (hold-relax-with agonist contraction)
Study: 20482275
Drug: High-maize 260
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-maize 260 resistant starch (12 g added RS)
Study: 12357148
Drug: Heparin concentration‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin concentration‐based anticoagulation management (Hepcon HMS)
Study: 12357148
Drug: Activated clotting
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated clotting time‐based heparin management
Study: 10348536
Drug: trapidil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: trapidil (400 mg/d) + ticlopidine (500 mg) for the first month
Study: 10348536
Drug: aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin (325 mg/d) + ticlopidine (500 mg) for the first month
Study: 7806173
Drug: Propranolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.15 mg/Kg intravenously)
Study: 1719734
Drug: NaCl-infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl-infusions
Study: 1719734
Drug: Zero or
Normalized name: Ez2go Zero Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zero or next to zero therapy
Study: 6176354
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with OK‐432 alone (group B)
Study: 31310775
Drug: 1 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mcg/kg intravenous ghrelin
Study: 31310775
Drug: 3 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mcg/kg intravenous ghrelin
Study: 25049338
Drug: 6-session intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-session intervention based on trauma-focused cognitive behavior therapy
Study: 18035192
Drug: Amlodipine camsylate
Normalized name: amlodipine camsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine camsylate 5 mg QD for 4 weeks, then increased to 10 mg QD if necessary for 4 weeks
Study: 18035192
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate 5 mg QD for 4 weeks, then increased to 10 mg QD if necessary for 4 weeks
Study: 12189228
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort (900 mg daily, orally for 18 days)
Study: 2104083
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg t.d.s.)
Study: 2104083
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg in the evening) without indomethacin
Study: 2104083
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg in the evening) with concurrent indomethacin
Study: 370586
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (200 mg per kilogram of body weight per day)
Study: 27817766
Drug: Somatostatin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (0.25 mg initial dose and 0.25 mg/h for maintenance)
Study: 27817766
Drug: Somatostatin (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (3.5 μg/(kg·h) continuous intravenous pumping)
Study: 17592905
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic agents (adjunctive treatment)
Study: 17592905
Drug: Placebo (adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (adjunctive treatment)
Study: 12818732
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL 25 mg once daily
Study: 8867274
Drug: Wobenzym (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wobenzym (4 x 7 capsules/day)
Study: 8867274
Drug: Diclofenac (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (2 x 50 mg capsules/day)
Study: 3931465
Drug: Glyburide once
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide once daily
Study: 3931465
Drug: Glyburide twice
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide twice daily
Study: 3931465
Drug: Chlorpropamide once
Normalized name: Chlorpropamide
DrugBank: Chlorpropamide (DB00672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpropamide once daily
Study: 31278117
Drug: Whey protein-based
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein-based nutritional supplement enriched with leucine and vitamin D
Study: 23907291
Drug: Neoadjuvant single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant single agent doxorubicin
Study: 19196813
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg x kg(‐1) human alpha(1)‐AT (Prolastin)
Study: 3814462
Drug: Nimodipine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (both doses)
Study: 2789070
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg four times daily (9 doses)
Study: 2789070
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg four times daily with ethamsylate 500 mg before each dose
Study: 25690515
Drug: Safer-drinking strategies
Normalized name: Safe-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safer-drinking strategies endorsed and implemented (e.g., eating prior to and during drinking, spacing drinks, reducing alcohol consumption)
Study: 24428305
Drug: Conventional weight‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional weight‐based dosing of GH (0.04 mg/kg/day)
Study: 24428305
Drug: GH dosing
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH dosing titrated to an IGF‐I target of 0 SDS (IGF0T)
Study: 24428305
Drug: GH dosing
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH dosing titrated to an IGF‐I target of +2 SDS (IGF2T)
Study: 23097066
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg subcutaneously every six months
Study: 19419595
Drug: Ziprasidone (80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (80-120 mg/d)
Study: 9541034
Drug: Smoked cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cocaine (up to 405 mg over 5 hours daily) for 4 days
Study: 9541034
Drug: Drug-free period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free period (2 days before and after cocaine administration)
Study: 8017448
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg at bedtime
Study: 2525415
Drug: Continuous hepatic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hepatic artery and intravenous infusion of FUDR (IA/IV group; 21 patients)
Study: 2525415
Drug: Hepatic artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic artery infusion alone (IA group; 23 patients)
Study: 23688934
Drug: SYNERGY ½
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNERGY ½ dose
Study: 21411610
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) ingestion (30 to 80 g/h, not exceeding 8%) during exercise
Study: 26876309
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg daily
Study: 9351079
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g/day; n = 18)
Study: 3812100
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of Azatadine
Study: 11287022
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) hCG administration
Study: 11287022
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) hCG administration
Study: 11287022
Drug: Both SC
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both SC and IM hCG administration
Study: 30224390
Drug: Low-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interleukin-2 (aldesleukin; dose range 0.3-3×10^6 IU)
Study: 17581445
Drug: TF-CBT +
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TF-CBT + sertraline
Study: 15608430
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 or 4 mg daily
Study: 10458396
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid treatment with improved hygiene
Study: 7822521
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine (2.5 mg/kg/day, adjusted to 5.0 mg/kg/day)
Study: 7822521
Drug: Etretinate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (0.5 mg/kg/day, adjusted to 0.75 mg/kg/day)
Study: 7822521
Drug: Cyclosporine replaced
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine replaced by topical dithranol (anthralin)
Study: 7822521
Drug: Etretinate followed
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate followed by topical dithranol
Study: 25819853
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg once daily plus clopidogrel 75 mg daily for 12 months
Study: 25819853
Drug: Dose-adjusted vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted vitamin K antagonist (VKA) once daily
Study: 15551207
Drug: Combination vaccine
Normalized name: Hepatitis vaccine combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vaccine (RSV cpts‐248/404 and PIV3‐cp45), 10(5) plaque‐forming units of each per 0.5‐mL dose
Study: 15551207
Drug: Monovalent PIV3
Normalized name: rotavirus, monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent PIV3 vaccine
Study: 15551207
Drug: Monovalent RSV
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent RSV cpts‐248/404 vaccine
Study: 15551207
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (combination and monovalent)
Study: 9407422
Drug: Lowest tertile
Normalized name: textiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest tertile of baseline proteinuria (< 2.5 g/24 hr)
Study: 9407422
Drug: Middle tertile
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle tertile of baseline proteinuria (2.5 to 4.3 g/24 hr)
Study: 9407422
Drug: Highest tertile
Normalized name: textiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest tertile of baseline proteinuria (> 4.3 g/24 hr)
Study: 8504651
Drug: Aminophylline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (4 mg/kg bolus followed by 2.5 mg/kg every 6 hrs x three doses, then 1.5 mg/kg every 6 hrs)
Study: 1742507
Drug: Ranitidine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine therapy
Study: 2890820
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sleeping with the bed-head raised and ranitidine therapy
Study: 26614597
Drug: ibandronate 1
Normalized name: ibandronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibandronate 1 mg/month
Study: 26614597
Drug: risedronate oral
Normalized name: risedronate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: risedronate oral 2.5 mg/day
Study: 14600927
Drug: Adenosine (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (140 micro g/kg/min) with low level exercise protocol (300 MBq and 700 MBq Tc‐99m tetrofosmin for stress and rest respectively)
Study: 10573515
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (13‐15 mg/kg daily)
Study: 6859584
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine epidurally
Study: 6859584
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg morphine epidurally
Study: 6859584
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg morphine epidurally
Study: 31349042
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus adjuvant radiation therapy (S+ART)
Study: 31349042
Drug: Surgical monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical monotherapy (SM)
Study: 31119692
Drug: Esaxerenone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaxerenone (5 mg) administered in the fasting state as a single oral dose
Study: 31119692
Drug: Esaxerenone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaxerenone (5 mg) administered in the postprandial state as a single oral dose
Study: 31119692
Drug: Fasting intravenous
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting intravenous administration of esaxerenone
Study: 31119692
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of fasting versus postprandial oral administration of esaxerenone
Study: 25491433
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER 4 mg/day
Study: 18381905
Drug: DMXB-A (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMXB-A (lower dose)
Study: 2178941
Drug: Parenteral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral estrogen (polyestradiol phosphate 80 or 160 mg i.m. monthly)
Study: 760745
Drug: Biperidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperidine (5 mg) administered intravenously to five patients after a single dose of PPZ-enanthate i.m.
Study: 760745
Drug: Oral PPZ
Normalized name: APAP 325/CTM 4/PPZ 25/PHENYLTOLOX 25MG C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PPZ treatment in fourteen patients with addition of biperidine or orphenadine given for 3 weeks in fixed oral doses.
Study: 760745
Drug: Concomitant antiparkinson
Normalized name: ANTIPARKINSON AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant antiparkinson therapy with PPZ.
Study: 25405562
Drug: Low MTV
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low MTV (<37.2 mL)
Study: 23193746
Drug: 3% minoxidil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% minoxidil lotion (MNX)
Study: 23193746
Drug: Combined 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 3% minoxidil and 0.1% finasteride lotion (MFX)
Study: 18607268
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum and fructooligosaccharides (synbiotic preparation)
Study: 1922206
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 1.25 mg per day
Study: 1922206
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 2 mg per day
Study: 1922206
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 0.1 mg twice a week
Study: 7065386
Drug: Infusion solutions
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion solutions warmed to body temperature and operation theatre temperature raised to 22-24 degrees C
Study: 31900273
Drug: Tai chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai chi exercise (12-week programme, 60 min per session, twice weekly)
Study: 31900273
Drug: Balance and
Normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Sunsolve MD Balance and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance and postural control training (12-week programme, 60 min per session, twice weekly)
Study: 24074720
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=17), home based physical therapy exercise program without isokinetic.
Study: 22372774
Drug: Triple-combination therapy
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide (OM/AML/HCTZ)
Study: 19732641
Drug: Warmed levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed levobupivacaine (20 mL of levobupivacaine 5 mg/mL + 0.005 mg/mL epinephrine at 40 degrees C)
Study: 19732641
Drug: Room-temperature levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room-temperature levobupivacaine (20 mL of levobupivacaine 5 mg/mL + 0.005 mg/mL epinephrine at 25 degrees C)
Study: 17263634
Drug: IDV/r 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDV/r 800/100 mg bid
Study: 15106814
Drug: Trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 2 mg (T)
Study: 15106814
Drug: Verapamil SR/trandolapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil SR/trandolapril 180/2 mg (V + T)
Study: 11805389
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (125 IU/kg, once weekly)
Study: 11805389
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (250 IU/kg, once weekly)
Study: 9746884
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (20 million KIU given over 30 h)
Study: 3258815
Drug: tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiaprofenic acid tablets 300 mg twice daily
Study: 3258815
Drug: tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiaprofenic acid sustained action (SA) capsules 600 mg once daily
Study: 3258815
Drug: indomethacin sustained
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: indomethacin sustained release (SR) capsules 75 mg once daily
Study: 3258815
Drug: tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiaprofenic acid SA capsules
Study: 3258815
Drug: indomethacin SR
Normalized name: Indomethacin SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin SR capsules
Study: 3258815
Drug: tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiaprofenic acid tablets
Study: 27600363
Drug: Acute naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute naltrexone treatment
Study: 25841041
Drug: Amisulpride 38.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 38.3 mg/d